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SchizophreniaSchizophrenia is one of the most common mental disorders to severely affect human health world-
wide. Single nucleotide polymorphisms (SNPs) within related genes are candidate susceptible fac-
tors for the disorder. Rs107822 within MiR219-1 and rs1625579 within MiR137 were genotyped in
589 cases and 622 controls to investigate the possible association between the loci and schizophre-
nia in a Chinese population. Our results showed significant association between rs107822 and the
disorder in allele (C vs. T: adjusted OR = 0.773, 95%CI = 0.655–0.912), co-dominant (TC vs. TT: adjusted
OR = 0.734, 95%CI = 0.571–0.943; CC vs. TT: adjusted OR = 0.655, 95%CI = 0.459–0.936), dominant (TC
+ CC vs. TT: adjusted OR = 0.707, 95%CI = 0.559–0.895), and recessive (CC vs. TC + TT: adjusted
OR = 0.724, 95%CI = 0.524–0.999) models, respectively. Meanwhile, negative associations were also
observed between rs107822 and the disorder in male and female subgroups, and genotype CC of
the locus was significantly associated with a lower positive symptom score of PANSS compared to
genotype TT carrier in the cases group. However, we didn’t observe a significant association between
rs1625579 and the disorder. These findings indicate that rs107822 within MiR219-1 might be
involved in pathogenesis of schizophrenia and that genotypes TC, CC and allele C of the locus are
protective factors for schizophrenia in a Chinese population.
 2015 The Authors. Published by Elsevier B.V. on behalf of the Federation of European Biochemical Societies. This
is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Schizophrenia is a one of the most common psychiatric disor-
ders that ranks among the top ten leading causes of long-term dis-
ability [1], and approximately 1% of the general population suffer
from this disorder worldwide [2]. Despite the rapid advance in
research on schizophrenia, the etiology of the disorder remains
poorly understood. It is known that interactions between environ-
mental and personal genetic factors can lead to the disorder, espe-
cially personal genetic background that plays a dominant role in
onset of schizophrenia [3–5]. Some studies showed that aberrant
expressions of mRNAs and proteins were observed in brain tissue
of schizophrenia patients [6–8], indicating that these encoding
genes and their regulated factors including microRNA (miRNA)
were involved in initiation and progression of the disorder.
MiRNA is an endogenous, abundant, small, non-coding and
single-stranded RNA of 17–25 nucleotides that can bind to the
30-untranslated region (UTR) of targeted mRNA to regulate the
expression at posttranscriptional level [9–11]. It regulates aboutone third of related genes and plays an important role in physio-
logical and pathophysiological processes, such as cell proliferation
and differentiation [12–14], organ growth and development [15]
and occurrence of neurological and psychiatric diseases [9,11]. Sin-
gle nucleotide polymorphism (SNP) in miRNA can lead to aberrant
expression or secondary structure change of the product and SNP
within 30-UTR binding site of its targeted gene may affect the affin-
ity between them [16–18]. And accumulating evidence reveals that
lots of miRNAs are expressed in bran tissue, and the most of them
are involved in differentiation and apoptosis of nerve cell and brain
development [12,13,15]. Moreover, aberrant expressions of miR-
NAs are observed in brain tissue of neuropsychiatric disorders
patients including schizophrenia [9,19], suggesting that abnormal
expression of specific miRNA might be an important element in
development of schizophrenia.
MiR-137, a brain-enriched expression miRNA, is an important
element in regulation of embryonic neural stem cells differentia-
tion [20], neuron proliferation and development [21], and synapsis
maturation [22]. Dysregulation of miR-137 can lead to abnormal
expression of its targeted genes, eventually leading to neuropsy-
chiatric disorders [23]. Rs1625579, which is an intron SNP in
MiR-137, has been identified as a susceptible locus for
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However, emerging case-control studies showed an inconsistent
result in Chinese population [25–28].
MiR-219-1 is an important regulator in n-methy1-D-aspartate
glutamate receptors (NMDAR)-mediated glutamate signal pathway
[29]. The pathway is involved in synaptic plasticity and fast neuro-
transmission in brain, and disruption of its signal pathway can lead
to schizophrenia [30,31]. Calcium/calmodulin-dependent protein
kinase II gamma subunit (CAMKIIG) is a component of the signal
pathway, and it is a targeted gene of miR-219-1. Inhibition of
miR-219-1 in the murine brain can significantly modulate behav-
ioral responses by disrupting NMDAR signal transmission in vivo
[29]. Rs107822 is an allele T/C alternated polymorphism which is
located in flanking sequence-37 bp of pre-miR-219-1. Since emerg-
ing studies showed that SNP in miRNA or 30-UTR of its targeted
gene could affect the transcription process or interaction between
hsa-miR-219-1 and mRNA 30-UTR of its targeted gene. So we
hypothesized that rs107822 within pri-miR-219-1 would affect
its structure or expression, leading to neuropsychiatric disorders
such as schizophrenia.
In order to investigate the association between rs 107822
within MiR-219-1 and rs1625579 of MiR-137 and susceptibility
to schizophrenia, a hospital-based case-control study including
589 clinical confirmed schizophrenia and 622 healthy checking-
up individuals was carried out in present study.
2. Materials and methods
A total of 589 clinical confirmed and unrelated schizophrenia
patients (275 males: mean age = 39.51 ± 14.15; 314 females: mean
age = 43.33 ± 14.82 years) and 622 healthy checking-up individu-
als (291 males: mean age = 39.70 ± 13.3 years; 331 females:
41.08 ± 14.3 years) with free of clinical symptom and without
any other disease from January of 2014 to March of 2015 in the
Nantong Fourth People’s Hospital were recruited in present study.
The psychiatric evaluation of each patients were performed by
three psychiatrists according to the DSM-IV criteria for schizophre-
nia and psychotic symptoms were evaluated according to struc-
tured interviews for the Positive and Negative Symptom Scale
(PANSS). The controls were healthy checking-up individuals with-
out personal or family history of neuropsychiatric disorder or any
abuse of addictive drug. All included individuals are of Chinese
Han nationality, which consists of more than 95% of the general
population. 1 ml heparin-anticoagulated peripheral blood sample
of each participant was collected and stored at 80 C till extrac-
tion. The baseline characteristics such as sex, age, smoking and
drinking were retrieved from medical record. This study was
approved by the Ethical Committee of Nantong Fourth People’s
Hospital and all written informed consents were obtained from
all participants.
Human genomic DNA was extracted from 200 ll heparin-
anticoagulated peripheral blood using Tiangen human blood
genome isolation Kit (Tiangen, Beijing, China) according to the
manufacturer’s protocol. DNA concentration and purity were
detected by Ultraviolet spectrophotometer (Eppendorf, Hambrug,
German), DNA concentration of all eligible sample should be
higher than 200 ng/ll and A260/A280 ratio should be in the
interval of 1.8–2.1.
Genotypes of rs1625579 and rs107822 were detected by Taq-
Man genotyping discrimination assay using ABI7500 PCR system
(Applied Biosystems, Foster City, USA). The detection was per-
formed in a total volume of 5 ll which contained 10 ng genomic
DNA temple, 2.5 ll 2 * TaqMan PCR MasterMix, 2.5 ll 20 * SNP
Assay (including primer and FAM/VIC probe). After initial denatu-
ration at 95 C for 10 min, samples were amplified through 40
cycles (92 C for 15 s, 60 C for 1 min). Primer and probe sequencesof the two lociwere used according to the description by Guella
et al. [32] and Cheong et al. [33], respectively. In order to validate
the result, 5% PCR products were randomly selected to DNA
sequencing.
Genotype frequencies of the two loci in case and control groups
were obtained by counting. Hardy–Weinberg equilibrium (HWE)
software was used to evaluate the genotypes of the loci in controls
whether or not was fit for HWE. Two-sided student T test was
selected to compare the difference in quantitative data and per-
sonal chi-square test was used to examine distribution difference
of allele or genotype in two groups. Odds ratios (ORs) and 95% con-
fidence intervals (95%CIs) were selected to estimate the strength
between the two loci and risk of schizophrenia. All statistics were
performed using SPSS software 17.0 (SPSS Inc., Chicago, IL, USA)
and p < 0.05 was considered as statistical significance.
3. Results
DNA concentration of all samples was higher than 200 ng/ll,
and purity was in the interval of 1.8–2.1, thus all samples were
included in our study. The baseline characteristics of two groups
were described in Table 1. Clinical global impression rating scales
(CGI) in cases was 5.31 ± 0.60, and there was no significant differ-
ence in age, sex, status of smoking and drinking, BMI, Glu, TG, CHO,
LDL and HDL in two groups.
The gentoype and allele distributions of rs107822 and
rs1625579 in cases and controls were described in Table 2. p-
Value of HWE in two SNPs were larger than 0.05 (v2 = 0.002, p-
value = 0.988 for rs107822; v2 = 0.004, p-value = 0.952 for
rs1625579), suggesting that genotype distributions of the loci were
conformed to HWE. Genotype TT, TC, CC and allele T, C frequencies
of rs107822 within MiR-219-1 in case and control groups were
43.1% and 35.2%, 44.3% and 48.2%, 12.6% and 16.6%, 65.3% and
59.3%, 34.7% and 40.7%, respectively. Comparing to genotype TT
of the locus, frequencies of genotype TC (p = 0.022, adjusted
OR = 0.734, 95%CI = 0.571–0.943) and CC (p = 0.007, adjusted
OR = 0.655, 95%CI = 0.459–0.936) were significantly decreased in
cases, and a negative association was examined between allele C
of the locus and risk of schizophrenia (p = 0.003, adjusted
OR = 0.773, 95%CI = 0.655–0.912). The significant association was
also observed in dominant (p = 0.005, adjusted OR = 0.707, 95%
CI = 0.559–0.895), recessive (p = 0.049, adjusted OR = 0.724, 95%
CI = 0.524–0.999) models. However, we did not observe any signif-
icant difference of genotype and allele frequencies of MiR-137
rs1625579 between two groups in co-dominant, dominant, reces-
sive, over-dominant and allele models.
When stratifying cases into male and female subgroups, geno-
type CC (13.4% vs. 20.6%, p = 0.022, adjusted OR = 0.571, 95%
CI = 0.352–0.928), and allele C (35.1% vs. 41.4%, p = 0.028, adjusted
OR = 0.765, 95%CI = 0.600–0.975) of rs107822 were significantly
associated with a decreased risk of schizophrenia in male sub-
group. Meanwhile, negative associations were also observed
between rs107822 and the disorder in co-dominant (45.2% vs.
54.1%, p = 0.010, adjusted OR = 0.640, 95%CI = 0.460–0.897 for TC
vs. TT), dominant (57.0% vs. 67.1%, p = 0.009, adjusted OR = 0.650,
95%CI = 0.440–0.901), over-dominant (45.2% vs. 54.1%, p = 0.027,
adjusted OR = 0.700, 95%CI = 0.516–0.960) and allele (34.4% vs.
40.0%, p = 0.038, adjusted OR = 0.780, 95%CI = 0.623–0.989) genetic
models in female subgroups (Table 3).
Results of association between rs107822, rs1625579 and PANSS
scores were showed in Table 4. As shown in Table 4, rs1625579
was not associated with total, positive symptom, negative symp-
tom and general symptom scores in case group. Whereas, only pos-
itive symptom score in patient harbored genotype CC of rs107822
was significantly lower than those carrying genotype TT.
Table 1
Clinical features of case and control groups in present study.
Variables Cases (589) Percentage (%) Controls (622) Percentage (%) p-Value
Age (years, M + SD) 41.56 ± 15.97 40.63 ± 8.52 0.577*
Male/female 275/314 47.4%/52.6% 291/331 48.4%/51.6% 0.721#
Smoking (Yes/No) 277/312 47.0%/53.0% 295/327 47.4%/52.6% 0.889#
Drinking (Yes/No) 230/359 39.0%/61.0% 220/402 35.4%/64.6% 0.185#
BMI (kg/m2) 22.87 ± 0.67 – 23.02 ± 0.81 – 0.672*
Glu (mm/L) 5.68 ± 1.95 – 5.44 ± 0.75 – 0.721*
TG (mml/L) 1.27 ± 0.78 – 1.37 ± 0.90 – 0.823*
CHO (mml/L) 4.33 ± 0.95 – 5.30 ± 1.03 – 0.522*
LDL (mm/L) 2.24 ± 0.69 – 2.43 ± 0.68 – 0.786*
HDL (mm/L) 1.33 ± 0.33 – 1.35 ± 0.29 – 0.894*
CGI score 5.31 ± 0.60 – – – –
* p-Value was calculated by two-sided student T test.
# p-Value was calculated by chi-square test; CGI: clinical global impression rating scales.
Table 2
Genotype and allele distributions of rs107822 within miR-219-1 and rs1625579 of miR-137 in cases and controls.
Locus Model Genotype and allele Cases Controls p-Value* OR and 95%CI#
(589) (622) [1] [2]
Rs107822 Co-dominant TT 254(43.1%) 219(35.2%)
TC 261(44.3%) 300(48.2%) 0.022 0.750(0.587–0.959) 0.734(0.571–0.943)
CC 74(12.6%) 103(16.6%) 0.007 0.619(0.437–0.878) 0.655(0.459–0.936)
Dominant TT 254(43.1%) 219(35.2%)
TC/CC 335(56.9%) 403(64.8%) 0.005 0.717(0.569–0.904) 0.707(0.559–0.895)
Recessive TT/TC 515(87.4%) 519(83.4%)
CC 74(12.6%) 103(16.6%) 0.049 0.724(0.524–1.000) 0.724(0.524–0.999)
Over-dominant TT/CC 328(55.7%) 322(51.8%)
TC 261(44.3%) 300(48.2%) 0.172 0.854(0.681–1.071) 0.847(0.673–1.067)
Allele T 769(65.3%) 738(59.3%)
C 409(34.7%) 506(40.7%) 0.003 0.776(0.658–0.915) 0.773(0.655–0.912)
Rs1625579 Co-dominant TT 512(86.9%) 540(86.8%)
GT 72(12.2%) 79(12.7%) 0.820 0.961(0.683–1.352) 0.963(0.684–1.355)
GG 5(0.9%) 3(0.5%) 0.496 1.758(0.418–7.393) 1.714(0.409–7.275)
Dominant TT 512(86.9%) 540(86.8%)
GT/GG 77(13.1%) 82(13.2%) 0.955 0.990(0.709–1.383) 0.991(0.710–1.385)
Recessive TT/GT 584(99.1%) 619(99.5%)
GG 5(0.9%) 3(0.5%) 0.496 0.566(0.135–2.379) 0.570(0.135–2.401)
Over-dominant TT/GG 517(87.8%) 543(87.3%)
GT 72(12.2%) 79(12.7%) 0.802 1.045(0.743–1.470) 1.043(0.741–1.468)
Allele T 1096(93.0%) 1159(93.2%)
G 82(7.0%) 85(6.8%) 0.901 1.020(0.745–1.397) 1.021(0.745–1.398)
* p-Value was calculated by chi-square test.
# OR: odds ratio, 95%CI: 95% confidence interval, [1]: crude OR and 95%CI, [2]: OR and 95%CI was adjusted by age, sex and status of smoking and drinking.
776 Y.-J. Sun et al. / FEBS Open Bio 5 (2015) 774–7784. Discussion
Data from emerging evidence supports the general consensus
that schizophrenia is a heterogeneous and complex disorder with
genetic, environmental, psychological and social components
[34]. The disorder is leaded by dysfunction of related protein
encoding and non-coding genes that are involved in initiation
and progression of the disease. MiR-137 and MiR-219-1 are
involved in regulation of neuron development and maturation
[20–22] as well as NMDAR-signal pathway in synaptic plasticity
and brain fast neurotransmission [30,31], respectively. Genetic
variations of the two miRNAs may affect transcription process or
binding ability between the miRNA and its targeted gene and con-
tribute to aberrant expression of them, eventually triggering onset
of neuropsychiatric disorders including schizophrenia.
In our study, we conducted a case-control study including 589
clinical confirmed schizophrenia patients and 622 healthy
checking-up controls to investigate the association between
rs107822 within MiR-219-1 and rs1625579 within MiR-137 and
risk of the disorder. Our results showed that rs107822 were signifi-
cantly associated with a decreased risk of schizophrenia in co-
dominant, dominant, recessive and allele models, there was a nega-tive association between the locus and the disorder in male and
female subgroups, and genotype CC of the locus were significantly
associated with a lower positive symptom score of PANSS compar-
ing to genotype TT in cases group, indicating that rs107822 within
MiR-219-1 was involved in pathogenesis of schizophrenia, it might
be a susceptible locus and genotype TC and CC and allele C of the
locus might be protective factors for this disorder. Rs107822 has
been reported to affect the biological process from pri-miRNA-
219-1 to pre-miR-219-1 [35]. The SNP can influence the secondary
structure of pri-miR-219-1, and structure of pri-miR-219-1 carrying
allele Tmay bemore stable than it harbored allele C [36].MiR-219-1
was located at schizophrenia susceptible region of 6p21, and it was
significantly up-regulated in the brain dorsolateral prefrontal area
and serum of schizophrenia patients [31,37]. Additionally, miR-
219-1 can bind with CAMKIIG 30-UTR to regulate transcription and
translation of the targeted gene [38]. Since CAMKIIG is an important
downstream signal molecular in NMDAR signal pathway [39] and
aberrant expression of CAMKIIG contributed to dysfunction of
NMDARsignal pathway [40], leading tooccurrenceof schizophrenia.
However, we did not observe the significant association
between rs1625579 within MiR-137 and susceptibility to
schizophrenia in our study. The results showed that rs1625579
Table 3
Stratifying analysis between rs107822 within miR-219-1 and schizophrenia based on gender.
Stratification Model Genotype and allele Cases Controls p-Value* Adjusted OR and 95%CI#
Male Co-dominant TT 119(43.3%) 110(37.8%)
TC 119(43.3%) 121(41.6%) 0.606 0.910(0.632–1.309)
CC 37(13.4%) 60(20.6%) 0.022 0.571(0.352–0.928)
Dominant TT 119(43.3%) 110(37.8%)
TC/CC 156(56.7%) 181(62.2%) 0.185 0.795(0.570–1.118)
Recessive TT/TC 238(86.6%) 251(79.4%)
CC 37(13.4%) 60(20.6%) 0.058 0.652(0.412–1.019)
Over-dominant TT/CC 156(56.7%) 170(58.4%)
TC 119(43.3%) 121(41.6%) 0.686 1.071(0.766–1.450)
Allele T 357(64.9%) 341(58.6%)
C 193(35.1%) 241(41.4%) 0.028 0.765(0.600–0.975)
Female Co-dominant TT 135(43.0%) 109(32.9%)
TC 142(45.2%) 179(54.1%) 0.010 0.640(0.460–0.897)
CC 37(11.8%) 43((13.0%) 0.160 0.696(0.420–1.155)
Dominant TT 135(43.0%) 109(32.9%)
TC/CC 179(57.0%) 222(67.1%) 0.009 0.650(0.440–0.901)
Recessive TT/TC 277(88.2%) 288(87.0%)
CC 37(11.8%) 43((13.0%) 0.640 0.898(0.600–1.432)
Over-dominant TT/CC 172(54.8%) 152(45.9%)
TC 142(45.2%) 179(54.1%) 0.027 0.700(0.516–0.960)
Allele T 412(65.6%) 397(60.0%)
C 216(34.4%) 265(40.0%) 0.038 0.780(0.623–0.989)
* p-Value was calculated by chi-square test.
# OR: odds ratio, 95%CI: 95% confidence interval, OR and 95%CI was adjusted by age, sex and status of smoking and drinking.
Table 4
Association between rs107822 within miR-219-1 and PANSS scores in case group.
Characteristics Rs107822 Rs1625579
Genotype Genotype
PANSS scores CC CT TT GG GT TT
Total 86.90 ± 12.35 86.13 ± 13.11 88.33 ± 11.89 85.56 ± 13.28 85.98 ± 12.67 85.26 ± 13.08
Positive symptom 23.56 ± 3.32* 25.49 ± 4.96 26.88 ± 4.45 25.34 ± 3.43 24.98 ± 4.01 25.23 ± 3.98
Negative symptom 20.56 ± 7.43 18.32 ± 8.32 19.78 ± 7.98 20.11 ± 6.98 19.96 ± 7.03 20.01 ± 7.00
General symptom 42.78 ± 8.70 42.32 ± 7.90 41.67 ± 8.21 40.11 ± 7.90 41.04 ± 7.89 40.02 ± 7.78
* Positive symptom score of rs107822 CC genotype individuals is significantly lower than TT genotype carrier.
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type and allele of the locus couldn’t be susceptible factors for the
disease. Yuan et al reported that either allele or genotype of the
locus was not associated with the disease in a case-control and
meta-analysis in Chinese population [27]. Meanwhile, results of
Wang et al also reported no significant association between them
[28]. However, an positive association between the locus and
schizophrenia was reported in Chinese population and European
Caucasian ancestry [24–26], respectively. The following causes
may account for this conflict result. Populations from different geo-
graphical area may exist heterogeneity of personal genetic back-
ground. Although individuals are all Chinese population in
different regions [25,26,28], frequency of allele C within
rs1625579 is inconsistent with each other. Additionally, small
sample size in case and control groups may attenuate statistical
power in our study [41].
In conclusion, our findings indicated that rs1625579 within
MiR-137 was not associated with schizophrenia, however MiR-
219-1 rs107822 was involved in pathogenesis of schizophrenia,
and genotype TT, TC, and allele C of the locus were protective fac-
tors for the disorder. With limitation of our study, further multiple
central and well-designed epidemiological study with large sample
size are warrant to conduct to validate our findings.
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